Current Vascular Pharmacology

Current Vascular Pharmacology is a Bentham Science Publishers title founded in 2003 that follows the drug treatment of arterial and venous disease and the clinical pharmacology behind it.《Current Vascular Pharmacology》是 Bentham Science Publishers 于 2003 年创办的期刊，追踪动脉与静脉疾病的药物治疗以及其背后的临床药理学。

Its pages are given mainly to reviews and mini-reviews, with original research, short letters, debates and drug trial studies alongside, and its 2025 Journal Impact Factor stands at 2.4.版面以综述与小型综述为主，原创研究，简短来信，辩论与药物试验研究并列其间，其 2025 年影响因子为 2.4。

Scope

• Bentham Science describes the journal as a place where clinical and research-based reviews, mini-reviews and original papers meet, so that practitioners and laboratory workers read the same pages.出版方把本刊描述为临床综述，研究型综述，小型综述与原创论文汇合之处，执业医师与实验室研究者因此读到同一批版面。

• Review articles and mini-reviews form the core of each issue, and they are joined by original research articles, letters, debates, drug clinical trial studies and guest-edited thematic issues.综述与小型综述构成每期的骨干，原创研究论文，来信，辩论，药物临床试验研究以及客座编辑的专题期与之并列。

• Its stated purpose is to bridge the gap between clinical practice and research still in progress, so a reader can see how a trial result bears on the next clinic visit.该刊自述的宗旨是弥合临床实践与仍在进行的研究之间的落差，读者因此能看出一项试验结果如何影响下一次门诊。

• Vascular disease is named as the commonest cause of death in westernised countries, and the journal notes that its incidence is now rising steadily across developing countries.血管疾病被称为西方化国家最常见的死因，本刊并指出其发病率在发展中国家正持续上升。

• Much of the research it reports is directed at finding an effective treatment for acute vascular events, from myocardial infarction and stroke to acute lower limb ischaemia.它报道的研究有相当部分指向急性血管事件的有效治疗，涵盖心肌梗死，卒中与急性下肢缺血。

• Long-term treatment also receives steady attention, including symptomatic relief, and the journal covers the primary and secondary prevention that landmark randomised trials have supported over recent decades.长期治疗同样受到持续关注，包括症状缓解，本刊也覆盖近几十年里程碑式随机试验所支持的初级与二级预防。

• Because vascular care is shared work, the readership spans primary care physicians, nurse practitioners, cardiologists, vascular and cardiothoracic surgeons, general physicians, radiologists, clinical pharmacologists and stroke neurologists.血管疾病诊疗属于协作性工作，读者群因此横跨基层医师，执业护士，心脏科医师，血管与心胸外科医师，内科医师，放射科医师，临床药理学家以及卒中单元的神经科医师。

• Reviews of recently published trials and of newly marketed drugs are explicitly welcome, which keeps the journal close to the prescribing decisions made in ordinary daily practice.对新近发表试验与新上市药物的评论明确受到欢迎，这使得本刊贴近日常诊疗中的处方决策。

• Research-based reviews that look at future developments and at potential drug targets are accepted as well, so the title carries both bedside and laboratory bench material in one volume.关注未来研发方向与潜在药物靶点的研究型综述同样被接收，临床与实验室的材料因此并存于同一卷中。

• A communications section is meant to encourage debate, which gives readers a place to contest the conclusions of a review or of a recently published trial report.通讯栏目意在鼓励辩论，读者因此有一个场所去质疑某篇综述或某份新近试验报告的结论。

• Guest-edited issues gather a set of papers on one theme, usually a drug class or a vascular territory, and they are a regular feature rather than an occasional extra.客座编辑的专题期围绕一个主题汇集若干论文，主题常为某一类药物或某一血管区域，属于常规内容而非偶发的增刊。

• Dedicated drug clinical trial studies are published alongside the reviews, and the journal asks that such work speak to the treatment of patients rather than to animal models alone.专门的药物临床试验研究与综述并列刊出，本刊希望这类工作直接面向患者治疗，而不只停留在动物模型。

• Letters and short communications give authors room for a single clinical observation, a comment on method, or a correction that would not justify a paper of full length.来信与短篇通讯为作者留出空间，可容纳一项单独观察，一条方法学意见，或一处不足以撑起整篇论文的更正。

• Reviews of this kind are meant to update readers on the treatment of vascular disease, a phrase the journal uses for the whole span from risk factor to acute event.这类综述意在更新读者对血管疾病治疗的了解，本刊用这一说法涵盖从危险因素到急性事件的整个过程。

• The title sits between a pharmacology journal and a vascular medicine journal, and it is classified in both peripheral vascular disease and pharmacology categories for that reason.本刊处在药理学刊物与血管医学刊物之间，正因如此它在期刊分类中同时落在外周血管病与药学两个类目。

History

• Volume 1 number 1 appeared in March 2003, from Bentham Science Publishers in Sharjah, with San Francisco given as a second place of publication in the National Library of Medicine catalog record.第 1 卷第 1 期于 2003 年 3 月面世，出版方为沙迦的 Bentham Science Publishers，美国国家医学图书馆的著录还把旧金山列为第二出版地。

• Bentham Science launched it as one of its Current titles, a family of review-led journals that survey a field for working clinicians rather than report primary findings alone.Bentham Science 把它作为 Current 系列的一种推出，该系列以综述见长，面向执业医师梳理某一领域，而不只报告原创发现。

• The journal has carried the same title since 2003, so it has no former name, and the volume numbering runs unbroken from that first issue to the present.本刊自 2003 年以来一直沿用同一刊名，没有旧名可循，卷号从创刊号起连续至今未曾中断。

• Print and electronic editions have run in parallel since the start, with the print number 1570-1611 and the electronic number 1875-6212 registered for the same articles, and both are still current.印本与电子版自始并行，印本刊号 1570-1611 与电子刊号 1875-6212 登记的是同一批文章，两者至今均有效。

• Indexing came early, and the National Library of Medicine records uninterrupted full MEDLINE and PubMed coverage from volume 1 number 1, together with a place in the printed Index Medicus.收录来得很早，美国国家医学图书馆著录该刊自第 1 卷第 1 期起即为 MEDLINE 与 PubMed 全文收录，并列入印刷版《Index Medicus》。

• Six issues a year have been the pattern since 2010, a frequency that suits a slim title whose annual output has stayed at roughly twenty to thirty papers.自 2010 年起每年出六期，这一频率与一份年发文量维持在二三十篇的轻量刊物相称。

• Output ran above a hundred papers a year through the early 2010s, touching 140 in 2012, and has since settled back to a steady few dozen items of annual publication.2010 年代初的年发文量曾超过一百篇，2012 年达到 140 篇，此后回落并稳定在每年数十篇的规模。

• Its impact factor fell from 3.524 in 2022 to 2.8 in 2023 and 2.1 in 2024 before recovering to 2.4 in 2025, while the five-year measure, which smooths out such year-to-year swings, still stands at 3.6.其影响因子从 2022 年的 3.524 降至 2023 年的 2.8 与 2024 年的 2.1，2025 年回升至 2.4，五年期指标为 3.6。

• In the 2025 Journal Citation Reports it sits in the third quartile of peripheral vascular disease at 53 of 100, and in the third quartile of pharmacology and pharmacy at 215 of 356.在 2025 年的期刊引证报告中，它位于外周血管病类目第三象限，100 份中列第 53，在药理学与药学类目同样处于第三象限，356 份中列第 215。

• The same JCR snapshot counts 2274 citations to the title, 23 articles published in the year and 43 citable items, with an immediacy index of 1.2 and a cited half-life of 7.6 years.同一份快照记录该刊被引 2274 次，载文 23 篇，可被引条目 43 项，即年指标为 1.2，被引半衰期为 7.6 年。

• Gold open access accounts for 6.56 per cent of what it publishes, so most papers still reach readers through institutional library subscription or through the publisher's hybrid option.金色开放获取占其出版量的 6.56%，多数论文仍通过机构订阅或出版方的混合模式到达读者。

• Scopus also indexes the title, and its current CiteScore of 3.6 places the journal in the second quartile of cardiology and cardiovascular medicine, ranked 174 among 409 titles listed there.Scopus 也收录该刊，现行 CiteScore 为 3.6，在心脏与心血管医学类目中处于第二象限，409 份中列第 174。

• Bentham Science remains the publisher of record, and no transfer of the title to another house appears in the catalog entries held by Crossref and the National Library of Medicine.Bentham Science 一直是该刊的登记出版方，Crossref 与美国国家医学图书馆的著录中均无转手给其他出版机构的记录。

• Its MEDLINE abbreviation is Curr Vasc Pharmacol, and the bibliographic catalog traces a single continuous record from 2003 onward rather than a series of renamed or merged entries.其 MEDLINE 缩写为 Curr Vasc Pharmacol，著录从 2003 年起只有一条记录，并未出现一系列更名条目。

Editors

• Dimitri P. Mikhailidis, honorary professor in the Department of Surgical Biotechnology at University College London, is editor-in-chief, and his own work on lipids, statins and atherosclerosis runs through the journal's pages.Dimitri P. Mikhailidis 是伦敦大学学院外科生物技术系的名誉教授，担任本刊主编，他本人在血脂，他汀与动脉粥样硬化方面的研究也贯穿该刊版面。

• His base is the Royal Free Hospital campus in north London, where the clinical biochemistry department he long led became a centre for lipid and vascular risk work.他的工作地点在伦敦北部的皇家自由医院院区，他长期主持的临床生物化学系在那里成为血脂与血管风险研究的中心。

• Thematic issues are assembled by guest editors, who propose a set of papers, write the introduction, and are named on the journal site beside each such issue.专题期由客座编辑组织，他们提出论文组合，撰写导言，并在刊物网站上与该期并列署名。

• Submitted papers are sent to outside referees chosen by the editorial office, and the published record of each article carries the dates of receipt, revision and acceptance.来稿由编辑部选定外部审稿人评议，每篇文章的出版记录都标注收稿，修回与接受日期。

• Reviews and mini-reviews are usually invited, and authors who have not been asked are advised to send a short proposal to the editorial office before writing a full manuscript.综述与小型综述多为约稿，未获邀约的作者被建议先寄一份简短选题说明，再动笔写完整稿件。

• Original research and drug trial studies sit beside the reviews, and both are handled by the same editorial office in Sharjah rather than by separate section teams.原创研究与药物试验研究和综述并列，两类稿件都由沙迦的同一编辑部处理，并未分设栏目团队。

• Authors are asked to declare competing interests and the sources of any financial support, a standing requirement the publisher applies uniformly across its whole list of journals.作者须申报利益冲突与各项资助来源，这是出版方对其全部刊物统一执行的要求。

• Page proofs are sent to the corresponding author before publication, and the publisher also runs a paid language editing service for manuscripts whose English still needs work.校样在出版前送交通讯作者，出版方另为需要润色的稿件提供付费语言编辑服务。

• The editorial board is international in composition, and its members are listed with their institutions and countries on the journal's own site and on the publisher's article pages.编委会由多国学者组成，成员及其所在机构与国别在刊物网站和出版方的文章页上逐一列出。

• The communications section exists to let readers answer a published argument, and its pieces are shorter than reviews and carry a brief reply where one is warranted.通讯栏目存在的意义是让读者回应已发表的论点，其篇幅短于综述，必要时附一段简短答复。